Cancer Genetics promotes FHACT test for cervical cancer at ACOG Annual Clinical Meeting

April 28, 2014

Cancer Genetics, Inc. (CGI), provider of DNA-based cancer diagnostics, is participating in the Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG), being held through Wednesday in Chicago. The conference is hosting more than 200 exhibitors and features more than 400 original research posters and paper abstracts.

“This year’s ACOG meeting is a great opportunity for us to communicate the value of our proprietary FHACT test for the management of cervical cancer to the clinical community and thought leaders in this Congress,” says Jane Houldsworth, Vice President of Research and Development for CGI.  “FHACT is a non-invasive genomic test that can identify lesions that are caused by persistent HPV infection and that are more likely to progress to a higher grade. By allowing for a better screening of patients before referral for colposcopy, the test can provide physicians with important information in making treatment decisions and potentially reduce costs and procedures that add to U.S. healthcare costs.”

FHACT (FISH-based HPV-Associated Cancer Test) is a four-color FISH (fluorescence in situ hybridization) probe that can be used for cervical cancer screening as an additional test before referral for colposcopy. The test uses a combination of genetic markers to detect genetic abnormalities located at 3q, 5p, 20q, and chromosome 7. FHACT can be used on the remnant liquid cytology (Pap smear) specimen (no resampling). The test is offered at CGI’s CLIA laboratory in New Jersey. Learn more about FHACT.

Read more